The cardiotoxicity of anthracyclines, trastuzumab and other agents is of special importance to adjuvant breast cancer patients whose life expectancy is restored to normal but who may be left with cardiac abnormalities that can present years later. We systematically reviewed the design of current trials (including adjuvant studies) on the clinicaltrials.gov Web site. Surprisingly few specify primary or secondary cardiac end points. Although cardiac ultrasound (echocardiography) and multiple uptake gated acquisition scintigraphy remain the most frequent techniques for estimating left ventricular ejection fraction, there is no consistency in the degree of reduction from baseline or absolute value taken as indicating cardiotoxicity. The details given do not suggest that diastolic function (which may give earlier warning of problems) is a focus of interest. There is growing interest in troponin as a marker of myocyte death and brain natriuretic peptide as a marker of myocardial stress and possible heart failure (though their clinical usefulness has still to be adequately defined). The duration of follow-up in many adjuvant studies may not be sufficient to determine the risk of late cardiac events. The findings indicate a need to study and standardize cardiac toxicity assessments in oncology trials.
introduction Increasingly, breast cancer clinicians are focused on addressing toxicity and choosing adjuvant breast cancer regimens associated with a superior long-term toxicity profile. Two clear trends suggest that potential cardiac toxicity of systemic agents is of paramount relevance to those caring for patients with breast cancer. The first is the aging of the population and hence the burden of coexisting cardiac disease among women who may develop breast cancer. In the United States, the median age at breast cancer diagnosis is >60, and 20% of cases occur in women aged 75 years or older [1] . The second and highly positive trend is the rising number of women who, due to early detection of the disease and effective adjuvant therapies, are long-term survivors of breast cancer. According to the most recent USA data, the 5-year survival rate among women diagnosed in 1999-2005 is now 89% [1] . Women are, therefore, now living sufficiently long for delayed consequences of treatment to become increasingly apparent.
Anthracyclines have played a major role in improving the treatment of both metastatic and early breast cancer. In the latter setting, anthracycline-based combination chemotherapy reduced 10-year breast cancer mortality by an absolute 4.6% when compared with prior nonanthracycline adjuvant regimens [2] . The cardiotoxicity of anthracyclines, however, is well accepted [3] [4] [5] [6] . The phenomenon of late and irreversible congestive heart failure (CHF), which may surface as a clinical manifestation of myocyte death years or even decades after actual injury, is of particular concern [7] . The risk is cumulative, dose related and rises from 5% at a cumulative doxorubicin dose of 400 mg/m 2 to 16% at cumulative doses exceeding 500 mg/m 2 [8] . Using the SEER database, Pinder et al. [9] found a cumulative 38% rate of CHF over 10 years in women aged 66 years and older who had received adjuvant anthracyclines. This compared with a rate of 33% in women treated with regimens not containing an anthracycline and 29% in those with no adjuvant chemotherapy [9] . At doses with equivalent antitumor efficacy, biopsy data show epirubicin to cause less endomyocardial injury than doxorubicin [10] , although a recent meta-analysis failed to demonstrate a significant difference in risk of CHF [11] .
There is also concern about cardiotoxicity associated with the anti-HER-2 monoclonal antibody trastuzumab, now part of the standard of treatment of HER-2-positive breast cancer. In adjuvant treatment, adding this anti-HER-2 antibody to chemotherapy can reduce risk of disease recurrence or death by up to a third relative to nontrastuzumab control arms [12] . Unfortunately, some studies reported a fourfold to fivefold greater cardiac risk when trastuzumab was administered concurrently with taxanes after anthracyclines or sequentially after completion of chemotherapy [13, 14] . Recently, however, the NOAH trial comparing neoadjuvant chemotherapy plus trastuzumab followed by adjuvant trastuzumab to neoadjuvant chemotherapy alone reported only two cases of symptomatic CHF, accounting for <2% of patients [15] . While newer data may indicate that previous assumptions regarding the cardiac risk associated with trastuzumab, especially when given concurrently or sequentially with anthracyclines, were overestimated, there is still a high need for further investigation, long-term follow-up and caution.
While the cardiotoxicity is clearly different in nature, the added effect of trastuzumab on a patient who has already received or is receiving concomitant anthracyclines has raised concern regarding both short-term and long-term cardiac sequelae.
Unlike anthracycline cardiotoxicity, which is largely irreversible, patients experiencing CHF when taking trastuzumab often recover [14] . While anthracycline cardiotoxicity arises from oxidative stress, the problem with trastuzumab appears to lie in its inhibition of a HER-2-mediated mechanism designed to protect cardiac myocytes under stress [16] . It should be noted that many of the signaling pathways targeted by novel agents are also survival pathways in the cardiac myocyte, and significant cardiotoxicity has been reported in renal cell cancer patients treated with the multitargeted tyrosine kinase inhibitors, sunitinib and sorafenib [17] . The use of such agents in combination with conventional chemotherapy and with other targeted agents therefore gives rise to the possibility of previously unforeseen cardiotoxicities as well as the potentiation of preexisting cardiac risk factors or cardiac problems [16] .
The development of small molecule and monoclonal antibody modulators of signal transduction within and around the tumor cell has led to an unparalleled growth in the number of clinical trials in cancer. Force and Kerkela [16] estimated that >300 such agents are in clinical development. Our challenge is to maximize the benefits offered by the extended range of available therapies while minimizing toxicity. This requires scrupulous attention to the monitoring of cardiac function during treatment and-given our experience of the delayed presentation of cardiac injury in the form of CHF in patients who have received adjuvant anthracyclines-for a considerable period thereafter. This paper is appropriately timed. The temporary suspension of enrollment to trial E5103-in which bevacizumab was added to adjuvant anthracycline, cyclophosphamide and paclitaxel-shows the research community's alertness to the potential cardiotoxicity of combining novel and established agents. The six cases of CHF among the first 200 patients randomly assigned to bevacizumab were subsequently judged consistent with the known level of risk, and recruitment resumed [18] .
In this instance, the alarm was raised by the development of CHF. However, this occurs only after the heart's substantial reserves have been depleted. One of the intriguing aspects of anthracycline cardiotoxicity is that damage occurs at doses well below those required to cause symptoms and at cumulative dosages considerably lower even than those reliably associated with decline in left ventricular ejection fraction (LVEF) [19] . It has proven difficult to standardize LVEF thresholds (whether absolute level or fall from baseline), which should trigger dose adjustment or suspension, and indeed, the mode of imaging best suited to LVEF measurement in this context continues to be debated [20] . Although there has been increasing interest in the potential inclusion of biomarkers such as troponin I and type B natriuretic peptide (BNP) as predictors of early myocardial damage and incipient heart failure, there are as yet no prospective data showing their clinical validity. Biomarkers of cardiac stress or injury have considerable potential. Troponin I is now known to be released as a marker for myocyte destruction and therefore may be an important marker for both the magnitude of cell injury and the timing of such injury. BNP suggests cardiac strain that may be apparent at varying times but is not invariably associated with immediate cell injury as is the case with troponin I. While these biomarkers increasingly are incorporated into clinical trials, their use in the clinical management of patients has not been sufficiently studied to be incorporated into routine clinical use. While they may provide a clue for early damage or stress, altering a potentially effective regimen on the basis of these markers is, at least at the time of this writing, premature. Some clinicians use markers to identify patients who might be candidates for enhanced cardioprotection in the face of ongoing anthracycline administration [21] .
Another area of uncertainty concerns the value of cardioprotective agents. A Cochrane meta-analysis found that the iron chelator dexrazoxane significantly reduced the risk of CHF in patients treated with anthracyclines [22] . However, there is concern as raised by Swain et al. , that the use of this agent may lead to decreased efficacy of anthracycline-based therapy, which may be especially important in the curative adjuvant setting. Furthermore, this agent has not been fully studied in the prospective setting to address this issue [23] . These concerns are highlighted in the recent guidelines from the American Society of Clinical Oncology that concluded that there is no case for the routine use of dexrazoxane in the setting of adjuvant breast cancer [24] . The role of angiotensineconverting enzyme (ACE) inhibitors and beta-blockers in protecting against chemotherapy-induced cardiac damage is much discussed but has not been prospectively evaluated in controlled trials involving sufficiently large and representative groups of patients [3] . Based on mechanistic considerations of the anthracycline injury, interventions that decrease pre-or afterload should be cardioprotective, as has been suggested by the use of these agents [25, 26] .
In the context of these uncertainties, it is important and essential to review ongoing breast cancer trials to assess the nature of cardiovascular monitoring being used, the extent to which investigators have defined primary and secondary cardiac end points and the period over which patients are being followed to establish the risk of late toxic effects.
We set out to include studies that had as their main focus the detection or prevention of cardiotoxicity-through the use of cardioprotective agents or potentially less cardiotoxic cytotoxics, drug formulations or regimens. However, it was anticipated that the majority of the trials reviewed would be assessing cardiac end points among other potential adverse events linked to interventions aimed at improving anticancer efficacy. This paper is intended to provide an informed view of the way investigators are approaching the assessment of potential cardiotoxicity in the adjuvant, metastatic and neoadjuvant breast cancer settings.
methods
Using the term 'breast cancer' to search the clinicaltrials.gov database in January 2010 retrieved 3482 trials. Adding the terms 'cardiac toxicity, cardiotoxicity, cardiac myopathy and cardiomyopathy' yielded a total of 46 studies (1%) with a primary or secondary cardiac end point and these were the focus of our interest.
Descriptions of trial design were examined to obtain data (whenever it was provided) on the nature of the cardiovascular end points assessed (clinical signs and symptoms of CHF and LVEF), the techniques used to measure LVEF [multiple uptake gated acquisition (MUGA), echocardiography or magnetic resonance imaging (MRI)], the possible role of biomarkers such as troponin and BNP and the duration of follow-up. results the nature of the studies Among the 46 trials with cardiac end points, 26 were in the nonmetastatic setting and 14 in the metastatic setting. Additionally, we found six studies for which the principle purpose was to correlate imaging, biomarker or genetic variables with cardiac end points as a means of establishing factors predictive of increased risk. These observational studies are listed in Table 1 .
Among the 26 nonmetastatic trials (Table 2 ), 8 were phase III trials. Five of these 26 studies involved a liposomal formulation of doxorubicin. Five studies were directly concerned with potentially cardioprotective agents: one involved L-carnitine, two compare an ACE inhibitor with a beta-blocker, one used the angiotensin II antagonist candesartan and one the iron chelator dexrazoxane.
Fourteen of the studies focused on metastatic breast cancer patients (Table 3) . These included two phase III trials. Of these trials, five involved liposomal doxorubicin and one dexrazoxane.
The majority of the trials were evaluating new-targeted therapies. Twenty of the 41 interventional studies involved trastuzumab. Eight studies (including four of the trastuzumab trials) involved bevacizumab. Lapatinib was part of two studies and pazopanib of one. The high proportion of trials with cardiac end points that involve a drug acting on the HER-2 receptor is notable, given that this pathway is overexpressed only in a minority of breast cancer patients and presumably reflects the cardiotoxicity concerns surrounding such agents.
clinical end points and ventricular function
Several classification systems address the diagnosis of CHF and the grading of its severity [20] . The New York Heart Association (NYHA) classification is based essentially on limitations on activity and does not require measurement of cardiac function. However, measurement of LVEF is part of the Clinical Toxicity Criteria and of the Common Terminology Criteria for Adverse Events (CTCAE). Many trials in clinicaltrials.gov simply list 'cardiac events' or 'cardiotoxicity' as an end point and do not give details of CHF assessment. Where these are provided, use of CTCAE version 3.0 is the choice of six studies. Six state that their end point of cardiac events includes NYHA class 3-4 CHF.
Six trial entries provide the LVEF criteria used in defining an end point. Two studies-both involving liposomal doxorubicin and docetaxel in metastatic breast cancer (MBC)-use the same criteria: in a symptomatic patient, a fall of ‡5% to a value <50% or in an asymptomatic patient, a fall of ‡10% to a value of <50%. The remaining four studies do not make a distinction according to symptoms, but each uses different LVEF criteria: a fall of >10% to a level <55% or of >5% to a level <50%, a fall of >15% from baseline or of >10% to <50% and a fall of >15% from baseline or of <15% but to a value <45%. The final study, an observational follow-up of patients treated with anthracyclines and/or trastuzumab, has as an end point a 10% fall in LVEF from baseline.
There is also considerable variation in the imaging modalities used to measure LVEF. MUGA is the most popular tool and specified in 12 trials. This reflects its status as the most reproducible measure of LVEF [19] , but the use of MUGA in trials does not reflect the current preference in many centers for cardiac ultrasound, this is because of the elimination of radiation exposure, the reduced cost and the recent improvements in the reproducibility of the technique. Only 7 of the 12 trials noted above offer echocardiography as an alternative; a further two trials cite echocardiography as the imaging modality of choice: echocardiography with estimation of diastolic dysfunction has been cited by some investigators as the measure most sensitive to early cardiac damage [19] . MRI is used in four studies, but it should be noted that routine clinical use remains limited as it is very expensive and many centers may not yet have the clinical expertise necessary.
duration of follow-up
One of the main challenges in documenting potential cardiotoxicity is that duration of follow-up with ongoing studies is quite limited. And, indeed, review of the interventional studies listed in Table 2 shows the median duration of follow-up is only 1.5 years.
Adequate duration of follow-up is paramount in the adjuvant setting where largely irreversible myocardial damage caused during the period of anthracycline exposure is prone to exacerbation over the patient's subsequent lifetime through an accumulation of stressors, such as hypertension and coronary artery disease. It is therefore encouraging that three major ongoing adjuvant phase III trials specify cardiac events as a secondary end point and involve follow-up of several years (Table 2 ). These are the PHARE trial comparing 6 versus 12 months of trastuzumab in combination with chemotherapy, which will follow patients for 5 years; the SHORT-HER trial of 3 versus 12 months' trastuzumab in association with chemotherapy, which specifies a follow-up of 'up to' 3 years and the BETH trial, assessing the possible additional benefit of bevacizumab, with a 5-year follow-up. Together, these studies intend to accrue 9400 patients. Of the interventional phase II studies, one study-involving treatment with doxorubicin, cyclophosphamide, lapatinib and paclitaxel-plans to follow patients for 10 years. However, two trials involving bevacizumab (combined with a TAC or TCH regimen) plan to follow patients for only 1 year, and a trial of epirubicin, cyclophosphamide, docetaxel, trastuzumab and bevacizumab has a follow-up of only 18 months.
Interestingly, the studies of potential cardioprotective agents also have a wide range of follow-up duration. The dexrazoxane study intends to follow patients for up to 10 years. The trial involving perindopril and bisoprolol will look at effects on left ventricular remodeling over a period of 3.5 years. However, the studies of lisinopril versus carvedilol and of L-carnitine will assess potential cardiac benefits for just 1 year, and the candesartan trial will follow patients for only 6 months.
Of the 14 studies in MBC, 2 (both involving liposomal doxorubicin) define an end point in terms of LVEF decline. But both confine the period of monitoring to the duration of treatment. Among the remaining studies, the longest planned follow-up is 3 years and the shortest 30 days after the end of treatment.
observational studies
Information about the end points and assessment techniques used in the observational studies has been included above where appropriate. However, these studies are also worth considering in their own right since they have the potential to cast considerable light on important questions. Two studies are directly considering whether contrast-enhanced cardiac MRI can augment the information provided by MUGA scans. The majority are assessing biomarker and other factors potentially predictive of cardiotoxicity and often in a very thorough way. The trial, NCT00875238, for example, is correlating National Cancer Institute-CTCAE grade 1 or greater cardiotoxicity with gene polymorphisms; biomarkers, including neuregulin, cardiotrophin-1, BNP and troponin; heart rate variability; ID, clinicaltrials.gov ID for this trial; agents, agents used in the treatment regimen; cardiac EP lists the cardiac end point(s) used in the particular trial; diagnostic tools indicate the methods used to monitor cardiac function; follow-up until catalogs how long patients were followed-up with regard to the cardiac end point; Pts lists the number of patients included in the trial. A, doxorubucin; Bev, bevacizumab; BNP, type B natriuretic peptide; C, cyclofosfamide; CAF, combination chemotherapy with cyclophosphamide, doxorubicin and fluorouracil; Cb, carboplatin; CHF, congestive heart failure; CMF, combination chemotherapy with cyclophosphamide, methotrexate and fluorouracil; CTCAE, Common Terminology Criteria for Adverse Events; E, epirubucin; Echo, echocardiography; EGF, epidermal growth factor; H, trastuzumab; IGF-1, insulin-like growth factor-1; IL-6, interleukin 6; L, lapatinib; lpD, liposomal doxorubicin; LVEF, left ventricular ejection fraction; MRI, magnetic resonance imaging; MUGA, multiple uptake gated acquisition; NCI, National Cancer Institute; nd, no data available; NYHA, New York Heart Association; P, paclitaxel; T, docetaxel; T, taxane; Tam, tamoxifen; VEGF, vascular endothelial growth factor. 
discussion
Despite the growing concern about cardiotoxic side-effects of new agents in breast cancer, a surprisingly small number of ongoing trials are including cardiac end points in their trial design. Taken collectively, the few current clinical trials in breast cancer, that do include a cardiac end point, seek to address many important cardiac issues that have recently been identified. These include the role of biomarkers as an indication of subclinical cardiac damage, the potential cardioprotective effects of beta-blockers and inhibitors of the angiotensin system and the contribution that may be made by less cardiotoxic cytotoxic agents, such as liposomal anthracycline formulations. Such research reflects our increasing concern that today's cancer survivors do not become tomorrow's cardiac patients. However, the variation in the design of these trials in terms of cardiac end points used will limit our ability to use the data generated to compare the cardiotoxicity of various agents and the potential benefit of protective strategies. One particular problem is the considerable heterogeneity in the way different studies are assessing cardiotoxicity. One can assume that the number of definite or probable cardiac deaths is routinely used as an outcome, but there is no standardization on how to measure the key variable neither of LVEF nor in the degree of change needed to constitute an event. A drop considered noteworthy in the trials reviewed here can be 5%, 10% or 15% and the perceived lower limit of normal 45%, 50% or 55%. In the search for standardization, might there be gains from greater involvement of cardiologists more centrally in trial design and not just in the screening of patients for cardiovascular risk and the management of toxicity? Along with greater standardization in the use of traditional end points, such as LVEF, there is a need for prospective validation and integration of novel end points and means of diagnosis, such as diastolic dysfunction and biomarkers.
The duration of follow-up appropriate to a trial of adjuvant therapy must balance the need to establish safety against the equally pressing need to bring highly active agents rapidly into this potentially curative setting. ID, clinicaltrials.gov ID for this trial; phase, phase of the clinical trial; agents, agents used in the treatment regimen; cardiac EP lists the cardiac end point(s) observed in the particular trial; diagnostic tools indicate the methods used to monitor cardiac function; follow-up duration catalogs how long patients were followed-up with regard to the cardiac end point; Pts lists the number of patients included in the trial. a All BC. A, doxorubucin; Bev, Bevacizumab; BNP, type B natriuretic peptide; C, cyclofosfamide; CHF, congestive heart failure; Cb, Carboplatin; CMF, combination chemotherapy with cyclophosphamide, methotrexate and fluorouracil; E, epirubucin; Echo, echocardiography; GM-CSF, granulocyte-macrophage colonystimulating factor; H, trastuzumab; LVEF, left ventricular ejection fraction; L, lapatiniblpD, liposomal doxorubicin; nd, no data available; MRI, magnetic resonance imaging; MUGA, multiple uptake gated acquisition; P, paclitaxel; T, docetaxel; T, Taxane; Tam, tamoxifen.
